Disease‐specific quality of life ‐ not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to recurrence
Postoperative MMC‐EMDA induction may leads to lower time to recurrence compared with MMC‐PD induction therapy (low certainty).
1 finding from 1 review
Time to progression
1 finding from 1 review
Serious adverse events
It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with MMC‐PD induction therapy (very low certainty).
1 finding from 1 review
Disease‐specific survival
1 finding from 1 review
Time to recurrence
Single‐dose, preoperative MMC‐EMDA probably leads to lower time to recurrence compared with single‐dose, postoperative MMC‐PD (moderate certainty).
1 finding from 1 review
Time to progression
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes time to progression compared with single‐dose, postoperative MMC‐PD (very low certainty).
1 finding from 1 review
Serious adverse events
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with single‐dose, postoperative MMC‐PD (very low certainty).
1 finding from 1 review
Disease‐specific survival
Single‐dose, preoperative MMC‐EMDA showed no clear difference in disease‐specific survival compared with single‐dose, postoperative MMC‐PD (low certainty).
1 finding from 1 review
Disease‐specific quality of life ‐ not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to recurrence
It is very uncertain whether postoperative MMC‐EMDA induction changes time to recurrence compared with postoperative BCG induction therapy (very low certainty).
1 finding from 1 review
Time to progression
1 finding from 1 review
Serious adverse events
It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with postoperative BCG induction therapy (very low certainty).
1 finding from 1 review
Disease‐specific survival
1 finding from 1 review
Disease‐specific quality of life ‐ not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to recurrence
Single‐dose, preoperative MMC‐EMDA probably leads to lower time to recurrence compared with TURBT alone (moderate certainty).
1 finding from 1 review
Time to progression
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes time to progression compared with TURBT alone (very low certainty).
1 finding from 1 review
Serious adverse events
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with TURBT alone (very low certainty).
1 finding from 1 review
Disease‐specific survival
Single‐dose, preoperative MMC‐EMDA showed no clear difference in disease‐specific survival compared with TURBT alone (moderate certainty).
1 finding from 1 review
Disease‐specific quality of life ‐ not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found